Review

Asian Journal of Andrology (2007) 9, 8–15; doi:10.1111/j.1745-7262.2007.00224.x

Gene therapy and erectile dysfunction: the current status

David H W Lau1,2,3,4, Sashi S Kommu5, Emad J Siddiqui2,3,4, Cecil S Thompson2,3, Robert J Morgan1, Dimitri P Mikhailidis2,3 and Faiz H Mumtaz4

  1. 1Department of Urology, Royal Free Hospital and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2QG, UK
  2. 2Department of Clinical Biochemistry, Royal Free Hospital and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2QG, UK
  3. 3Department of Surgery, Royal Free Hospital and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2QG, UK
  4. 4Department of Urology, Chase Farm Hospital, The Ridgeway, Enfield EN2 8JL, UK
  5. 5Institute of Cancer Research and The Royal Marsden Hospitals NHS Foundation Trust, Surrey SM2 5PT, UK

Correspondence: Dr David H. W. Lau, Department of Clinical Biochemistry, Royal Free Hospital, Pond Street, London NW3 2QG, UK. Fax: +44-207-830-2235. E-mail: htpdlau@aol.com

Received 26 January 2006; Accepted 16 June 2006.

Top

Abstract

Current available treatment options for erectile dysfunction (ED) are effective but not without failure and/or side effects. Although the development of phosphodiesterase type 5 (PDE5) inhibitors (i.e. sildenafil, tadalafil and vardenafil) has revolutionized the treatment of ED, these oral medications require on-demand access and are not as effective in treating ED related to diabetic, post-prostatectomy and severe veno-occlusive disease states. Improvement in the treatment of ED is dependent on understanding the regulation of human corporal smooth muscle tone and on the identification of relevant molecular targets. Future ED therapies might consider the application of molecular technologies such as gene therapy. As a potential therapeutic tool, gene therapy might provide an effective and specific means for altering intracavernous pressure "on demand" without affecting resting penile function. However, the safety of gene therapy remains a major hurdle to overcome before being accepted as a mainstream treatment for ED. Gene therapy aims to cure the underlying conditions in ED, including fibrosis. Furthermore, gene therapy might help prolong the efficacy of the PDE5 inhibitors by improving penile nitric oxide bioactivity. It is feasible to apply gene therapy to the penis because of its location and accessibility, low penile circulatory flow in the flaccid state and the presence of endothelial lined (lacunar) spaces. This review provides a brief insight of the current role of gene therapy in the management of ED.

Keywords:

gene therapy, nitric oxide synthase, erectile dysfunction, calcium-sensitive potassium channel, vascular endothelial growth factor, calcitonin gene-related peptide

Top

References

  1. NIH Consensus Conference. Impotence NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90. | PubMed | ISI |
  2. Lau DH, Mumtaz FH, Thompson CS, Mikhailidis DP. Erectile dysfunction: a need for greater awareness. J R Soc Health 2004; 124: 214–6. | Article | PubMed |
  3. Lau DH, Kommu S, Mikhailidis DP, Morgan RJ, Mumtaz FH. Re: the prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2005; 173: 1050. | PubMed |
  4. Gunduz MI, Gumus BH, Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian J Androl 2004; 6: 355–8. | PubMed | ISI | ChemPort |
  5. Son H, Park K, Kim SW, Paick JS. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117–20. | PubMed | ISI | ChemPort |
  6. Low WY, Ng CJ, Tan NC, Choo WY, Tan HM. Management of erectile dysfunction: barriers faced by general practitioners. Asian J Androl 2004; 6: 99–104. | PubMed | ISI |
  7. Gooren LJ, Saad F. Recent insights into androgen action on the anatomical and physiologicalsubstrate of penile erection. Asian J Androl 2006; 8: 3–9. | Article | PubMed | ChemPort |
  8. Kendirci M, Gur S, Sikka SC. Gene therapy for erectile dysfunction. Front Biosci 2005; 10: 2758–69. | Article | PubMed | ISI | ChemPort |
  9. Lau DHW, Kommu SS, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP. The management of ph osphodiesterase-5 (PDE5) inhibitor failure. Curr Vasc Pharmcol 2006; 4: 89–93. | Article | ChemPort |
  10. Latchman DS editor. From Genetics to Gene Therapy, The Molecular Pathology of Human Disease. Oxford: Bios Scientific Publishers; 1994.
  11. Crystal RG. Transfer of genes to humans early lessons and obstacles to success. Science 1995, 270: 404–10. | Article | PubMed | ISI | ChemPort |
  12. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996, 334: 1185–7. | Article | PubMed | ISI | ChemPort |
  13. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995, 2: 357–62. | PubMed | ChemPort |
  14. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 2004; 39: 1705–12. | Article | PubMed | ISI | ChemPort |
  15. Christ GJ. Gene therapy: future strategies and therapies. Drugs Today (Barc) 2000; 36: 175–84. | PubMed | ChemPort |
  16. Lee M, Ryu JK, Oh SM, Lee E, Shin HY, Song SU, et al. Water-soluble lipopolymer as a gene carrier to corpus cavernosum. Int J Impot Res 2005; 17: 326–34. | Article | PubMed | ChemPort |
  17. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine 2004; 23: 167–76. | Article | PubMed | ChemPort |
  18. Chancellor MB, Tirney S, Mattes CE, Tzeng E, Birder LA, Kanai AJ, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003; 91: 691–6. | Article | PubMed | ISI | ChemPort |
  19. Wagner J, Madry H, Reszka R. In vivo gene transfer: focus on the kidney. Nephrol Dial Transplant 1995, 10: 1801–7. | PubMed | ChemPort |
  20. Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995, 2: 97–104. | PubMed | ISI | ChemPort |
  21. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995, 52: 485–9. | Article | PubMed | ISI | ChemPort |
  22. Liu WJ, Xin ZC, Xin H, Yuan YM, Tian L, Guo YL. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005; 7: 381–8. | Article | PubMed | ChemPort |
  23. Sullivan ME, Mumtaz FH, Dashwood MR, Thompson CS, Naseem KM, Bruckdorfer KR, et al. Enhanced relaxation of diabetic rabbit cavernosal smooth muscle in response to nitric oxide: potential relevance to erectile dysfunction. Int J Impot Res 2002; 14: 523–32. | Article | PubMed | ISI | ChemPort |
  24. Thompson CS, Mumtaz FH, Khan MA, Wallis RM, Mikhailidis DP, Morgan RJ, et al. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur J Pharmacol 2001; 425: 57–64. | Article | PubMed | ISI | ChemPort |
  25. Khan MA, Thompson CS, Jeremy JY, Mumtaz FH, Mikhailidis P, Morgan RJ. The effect of superoxide dismutase on nitric oxide-mediated and electrical field-stimulated diabetic rabbit cavernosal smooth muscle relaxation. BJU Int 2001; 87: 98–103. | Article | PubMed | ISI | ChemPort |
  26. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995, 92: 1137–41. | Article | PubMed | ChemPort |
  27. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998, 97: 1274–81. | PubMed | ChemPort |
  28. Varenne O, Pislaru S, Gillijns H, van Pelt N, Gerard RD, Zoldhelyi P, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998, 98: 919–26. | PubMed | ISI | ChemPort |
  29. Chen AF, O'Brien T, Tsutsui M, Kinoshita H, Pompili VJ, Crotty TB, et al. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery. Circ Res 1997, 80: 327–35. | PubMed | ChemPort |
  30. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169: 1911–7. | Article | PubMed | ISI | ChemPort |
  31. Bivalacqua TJ, Champion HC, Mehta YS, Abdel-Mageed AB, Sikka SC, Ignarro LJ, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000; 12: 8–17. | Article |
  32. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004; 16: 21–9. | Article | PubMed | ISI | ChemPort |
  33. Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 1999; 96: 11648–52. | Article | PubMed | ChemPort |
  34. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998, 187: 295–306. | Article | PubMed | ISI |
  35. Tzeng E, Billiar TR, Williams DL, Li J, Lizonova A, Kovesdi I, et al. Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. Surgery 1998, 124: 278–83. | PubMed | ChemPort |
  36. Ding M, Zhang M, Wong JL, Rogers NE, Ignarro LJ, Voskuhl RR. Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 1998, 160: 2560–4. | PubMed | ISI | ChemPort |
  37. Garban H, Marquez D, Magee T, Moody J, Rajavashisth T, Rodiguez JA, et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1996, 56: 954–63. | Article |
  38. Chancellor MB, Tirney S, Mattes CE, Tzeng E, Birder LA, Kanai AJ, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int. 2003; 91: 691–6. | Article | PubMed | ISI | ChemPort |
  39. Tirney S, Mattes CE, Yoshimura N, Yokayama T, Ozawa H, Tzeng E, et al. Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adenovirus-transduced myoblast vectors. Mol Urol 2001; 5: 37–43. | Article | PubMed | ISI | ChemPort |
  40. Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004, 71: 1568–77. | Article | PubMed | ISI | ChemPort |
  41. Magee T, Fuentes AM, Garban H, Rajavashisth T, Marquez D, Rodriguez JA, et al. Cloning of a novel neuronal nitric oxide synthase expressed in the penis and lower urogenital tract. Biochem Biophys Res Commun 1996, 226: 146–51. | Article |
  42. Gonzalez-Cadavid NF, Burnett AL, Magee TR, Zeller CB, Vernet D, Smith N, et al. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves. Biol Reprod 2000, 63:704–14. | Article | PubMed | ISI | ChemPort |
  43. Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid NF. Effect of aging on nitric oxide-mediated penile erection in the rat. Am J Physiol 1995, 268: 467–75.
  44. Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid N F. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997, 138: 3925–32. | Article | PubMed | ChemPort |
  45. Vernet D, Cai L, Garban H, Babbitt ML, Murray F, Rajfer J, et al. Reduction of penile nitric oxide synthase in diabetic BB/ WORdp (Type I) and BBZ/WORdp (Type II) rats with erectile dysfunction. Endocrinology 1995, 136: 5709–17. | Article | PubMed | ISI | ChemPort |
  46. Xie Y, Garban H, Ng CH, Rajfer J, Gonzalez-Cadavid NF. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol 1997, 157: 1121–6. | Article | PubMed | ChemPort |
  47. Penson DF, Ng CH, Cai L, Rajfer J, Gonzalez-Cadavid NF. Androgen and pituitary control of nitric oxide synthase activity and erectile function in the rat penis. Biol Reprod 1996, 55: 567–74. | Article | PubMed | ChemPort |
  48. Xie Y, Garban H, Ng C, Rajfer J, Gonzalez-Cadavid NF. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol 1997; 157:1121–6. | Article | PubMed | ChemPort |
  49. Burnett AL, Nelson RJ, Calvin DC, Liu JX, Demas GE, Klein SL, et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996, 2: 288–96. | PubMed | ISI | ChemPort |
  50. Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002; 67: 1033–41. | Article | PubMed |
  51. Christ GJ, Spray DC, Brink PR. Characterization of K currents in cultured human corporal smooth muscle cells. J Androl 1993, 14: 319–28. | PubMed | ISI | ChemPort |
  52. Lee SW, Wang HZ, Zhao W, Ney P, Brink PR, Christ GJ. Prostaglandin E1 activates the large conductance KCa channel in human corporal smooth muscle cells. Int J Impot Res 1999; 11: 189–99. | Article | PubMed | ISI | ChemPort |
  53. Fan SF, Brink PR, Melman A, Christ GJ. An analysis of the Maxi-K+(KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995, 153: 818–25. | Article | PubMed | ISI | ChemPort |
  54. Christ GJ, Rehman J, Day N, Salkoff L, Valcic M, Melman A, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998; 275: 600–8.
  55. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004; 287: 1544–53. | Article |
  56. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur Urol 2005; 48: 314–8. | Article | PubMed | ISI | ChemPort |
  57. Gholami SS, Rogers R, Chang J, Ho HC, Grazziottin T, Lin CS, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol 2003; 169: 1577–81. | Article | PubMed | ChemPort |
  58. Rogers RS, Graziottin TM, Lin CS, Kan YW, Lue TF. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 2003; 15: 26–37. | Article | PubMed | ISI | ChemPort |
  59. Bennett NE, Kim JH, Wolfe DP, Sasaki K, Yoshimura N, Goins WF, et al. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005; 173: 1820–4. | Article | PubMed | ISI | ChemPort |
  60. Cormio L, Gesualdo L, Maiorano E, Bettocchi C, Palumbo F, Traficante A, et al. Vasoactive intestinal polypeptide (VIP) is not an androgen-dependent neuromediator of penile erection. Int J Impot Res 2005; 17: 23–6. | Article | PubMed | ChemPort |
  61. Champion HC, Wang R, Santiago JA, Murphy WA, Coy DH, Kadowitz PJ, et al. Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the feline erection model. J Androl 1997; 18: 513–21. | Article | PubMed | ISI |
  62. Shen ZJ, Wang H, Lu YL, Zhou XL, Chen SW, Chen ZD. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int 2005; 95: 890–4. | Article | PubMed | ISI | ChemPort |
  63. Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod 2001; 65: 1371–7. | Article | PubMed | ISI | ChemPort |
  64. Bai WJ, Hou SK, Wang XF, Yan Z, He P Y, Deng QP, et al. The effects of antisenes oligodeoxynucleotide on the cyclic nucleotide monophosphates in smooth muscle cells of human corpus cavernosum. Zhonghua Nan Ke Xue 2002; 8: 88–91. | PubMed | ChemPort |
  65. Lin G, Hayashi N, Carrion R, Chang LJ, Lue TF, Lin CS. Improving erectile function by silencing phosphodiesterase-5. J Urol 2005; 174: 1142–8. | Article | PubMed | ISI | ChemPort |
  66. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 2004; 101: 9121–6. | Article | PubMed | ChemPort |
  67. McCobb DP, Fowler NL, Featherst T, Lingle CJ, Saito M, Krause JE, et al. Human calcium-activated potassium channel gene expressed in vascular smooth muscle. Am J Physiol 1995; 269: 767–77.
  68. Moelling K. Naked DNA-the poor man's gene therapy? Gene Ther 1998; 5: 573–4. | Article | PubMed | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

RESEARCH

Vascular endothelial growth factor (VEGF) gene therapy using a nonviral gene delivery system improves erectile function in a diabetic rat model

International Journal of Impotence Research Original Article

See all 14 matches for Research

Extra navigation

.

natureproducts


ADVERTISEMENT